Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has reported positive top-line results from its studies in June 2023, reinforcing confidence in its therapeutic developments for neurodegenerative diseases. The company's innovative drug candidates, AL001 and AL002, aim to address critical medical needs in the treatment of conditions such as Alzheimer's disease, positioning it favorably within the biopharmaceutical market. Additionally, the current valuation of Alzamend Neuro is deemed attractive, with analysts indicating that the achievement of upcoming key milestones and positive data could serve as significant catalysts for the stock's performance.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which considerably exceeded the company's previous estimates of $(0.69). The company faces significant challenges related to balance sheet and liquidity risks, as well as the potential failure of its drug candidates to demonstrate safety and efficacy in clinical trials, which could hinder regulatory approvals and commercialization efforts. Additionally, external factors such as competition, shifting macroeconomic conditions, and changing healthcare priorities could further complicate the company's prospects and undermine investor confidence in its stock.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.